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 BACKGROUND 
•Schistosomiasis is a neglected tropical disease, endemic in 76 countries, that afflicts more than 240 million people. Symmers' 
portal fibrosis (also called periportal fibrosis) is a characteristic hepatic disease described in schistosomiasis.  
•Although estimates are not available, Schistosomiasis must still be considered to be the most frequent cause of liver fibrosis 
worldwide.  
•Angiogenesis, the formation of new blood vessels from pre-existing ones, is recognized as a key event in a basic change 
occurring during repair by granulation tissue. This process seems to precede fibrosis formation in most types of chronic liver 
disease (Fig. 2). 
Fig. 1: Angiogenesis in S. haematobium-associated 
bladder cancer. 
METHODOLOGICAL STRATEGY 
RESULTS 
CONCLUSIONS 
 By immunohistochemical staining using IL-6 as inflammation marker, Von Willebrand (CD31) as endothelial marker, Microvessel Density 
(MVD) as angiogenesis marker and LYVE-1 as lymphangiogenesis marker in the livers of normal control mice and S. mansoni infected mice.  
 
• S. mansoni infection increases inflammation,  angiogenesis and lymphangiogenesis in the liver. 
•Thus, blocking  blocking IL-6 and /or lymph/angiogenesis may represent the appropriate therapeutic target for the treatment of schistosomal liver fibrosis. 
 
 
Fig. 2: Liver pathology and fibrosis in murine schistosomiasis 
mansoni. (Left non-infected and Right Infected mice) 
AIM 
To study angiogenesis in the livers of mice infected with S. mansoni. 
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